<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9DABACE4-5A03-427C-AC69-A78C03BD4CA9"><gtr:id>9DABACE4-5A03-427C-AC69-A78C03BD4CA9</gtr:id><gtr:name>Immunobiology Ltd, Babraham, UK</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C26EC5DC-44D6-4728-8540-416E1CC7A2CB"><gtr:id>C26EC5DC-44D6-4728-8540-416E1CC7A2CB</gtr:id><gtr:name>University of Lisbon</gtr:name><gtr:address><gtr:line1>Campo Grande</gtr:line1><gtr:line2>Edificio C5</gtr:line2><gtr:line3>1749-016</gtr:line3><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E6DF5D67-D7D6-4891-9B77-959BE9D17DAC"><gtr:id>E6DF5D67-D7D6-4891-9B77-959BE9D17DAC</gtr:id><gtr:name>The Walter and Eliza Hall Institute of Medical Research</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:department>Finance</gtr:department><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9DABACE4-5A03-427C-AC69-A78C03BD4CA9"><gtr:id>9DABACE4-5A03-427C-AC69-A78C03BD4CA9</gtr:id><gtr:name>Immunobiology Ltd, Babraham, UK</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C26EC5DC-44D6-4728-8540-416E1CC7A2CB"><gtr:id>C26EC5DC-44D6-4728-8540-416E1CC7A2CB</gtr:id><gtr:name>University of Lisbon</gtr:name><gtr:address><gtr:line1>Campo Grande</gtr:line1><gtr:line2>Edificio C5</gtr:line2><gtr:line3>1749-016</gtr:line3><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E6DF5D67-D7D6-4891-9B77-959BE9D17DAC"><gtr:id>E6DF5D67-D7D6-4891-9B77-959BE9D17DAC</gtr:id><gtr:name>The Walter and Eliza Hall Institute of Medical Research</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/B54F1402-B535-46A3-B1DA-E905717D7FF8"><gtr:id>B54F1402-B535-46A3-B1DA-E905717D7FF8</gtr:id><gtr:firstName>Philip</gtr:firstName><gtr:surname>Stevenson</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0400427"><gtr:id>E327EB52-54E7-414B-99BD-101B4F21C841</gtr:id><gtr:title>Gamma-herpesvirus dissemination in vivo</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0400427</gtr:grantReference><gtr:abstractText>The gamma-herpesviruses are a major cause of disease. This reflects the capacity of viral gene expression to evade the host defence mechanisms encoded by the human genome. While there has been enormous investment in the analysis of both host and pathogen DNA sequences, we have very little idea how the relevant proteins interact in vivo. With the gamma-herpesviruses, this reflects a relative lack of suitable experimental models with which to analyze host / pathogen interactions. We are using the MHV-68 model to address, in an important class of complex parasites, this deficit in our understanding of immune gene function .
Our research findings are communicated principally in specialist journals. We regularly present unpublished data at scientific meetings. Information is communicated directly to the public at university open days, departmental seminars and via the departmental and divisional web sites.</gtr:abstractText><gtr:technicalSummary>The gamma-herpesviruses represent a significant and difficult clinical problem. They are complex pathogens, with 80-100 genes, that persist and remain infectious despite established immunity. Our knowledge of how individual genes contribute to the pathogenesis of human gamma-herpesviruses is extremely limited, since modified viruses can be studied only in vitro. We are therefore using a natural murid gamma-herpesvirus, MHV-68, to identify genes crucial to in vivo host colonization. All gamma-herpesviruses are latent in lymphocytes and the entry of virus into lymphoid tissue is a key event. There is no viraemia. Instead, an initial epithelial infection probably reaches lymphoid tissue via direct contact between infected and uninfected cells. We have preliminary evidence that gp48, a product of the MHV-68 ORF27 gene, which has homologues in all gamma-herpesviruses, is a critical determinant of cell to cell spread in vitro; and that a multiple membrane spanning protein encoded by ORF58 is required for gp48 expression at the cell surface. The aims of this project are to determine how gp48 and the ORF58 gene product act at a molecular level and to characterize the effect of gp48 and ORF58 deficits in vivo.</gtr:technicalSummary><gtr:fund><gtr:end>2008-04-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2005-05-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>244006</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Lisbon</gtr:collaboratingOrganisation><gtr:country>Portugal, Portuguese Republic</gtr:country><gtr:description>lisbon collaboration</gtr:description><gtr:id>30DD7A96-3A94-4620-90C2-4B61027676E5</gtr:id><gtr:impact>19605591 19088269 18846211</gtr:impact><gtr:outcomeId>291C589FA7A-1</gtr:outcomeId><gtr:partnerContribution>joint research projects</gtr:partnerContribution><gtr:piContribution>joint research projects</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Walter and Eliza Hall Institute of Medical Research (WEHI)</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:department>Immunology Division</gtr:department><gtr:description>WEHI collaboration</gtr:description><gtr:id>62713E13-8DB7-4D8C-8D0E-29DD5499693B</gtr:id><gtr:impact>17109468 18025195 travelling fellowship from Royal Society to visit WEHI lab joint Wellcome Trust project grant</gtr:impact><gtr:outcomeId>05C2BA53F81-1</gtr:outcomeId><gtr:partnerContribution>joint research project</gtr:partnerContribution><gtr:piContribution>collaborative experiments with Gabrielle Belz</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Immunobiology Ltd, Babraham, UK</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>bbsrc case</gtr:description><gtr:id>B87A4739-74A3-4491-82AB-845581F8E3DA</gtr:id><gtr:impact>19625459</gtr:impact><gtr:outcomeId>2174F639CC3-1</gtr:outcomeId><gtr:partnerContribution>discussion of project provision of biotechnology experience to student</gtr:partnerContribution><gtr:piContribution>BBSRC CASE studentship with Immunobiology</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>department open days</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>80738B31-D7CB-4871-AB5B-336DE1555453</gtr:id><gtr:impact>virology presentation at department open day

information exchange</gtr:impact><gtr:outcomeId>21CDC62D920</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006,2007,2008</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1056697</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC program grant</gtr:description><gtr:end>2013-06-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>7C497F22-386C-4B89-8A86-170B72DBCE9E</gtr:id><gtr:outcomeId>prczTVcNt4q0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-06-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>generated monoclonal antibodies against viruses, and recombinant viruses</gtr:description><gtr:id>2B9D6056-DD49-46CF-8074-03BC149D4382</gtr:id><gtr:impact>unknown as yet</gtr:impact><gtr:outcomeId>26DBF1E66E3</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>antibodies +  viruses</gtr:title><gtr:type>Antibody</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>system for imaging virus infection in live mice</gtr:description><gtr:id>967DCDB6-73F2-401C-B901-B2B202924229</gtr:id><gtr:impact>reduced mouse use</gtr:impact><gtr:outcomeId>75E197411AC</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>luciferase imaging</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type><gtr:yearFirstProvided>2008</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>90013554-842B-4946-A81C-C1883D6FC833</gtr:id><gtr:title>Bovine herpesvirus type 4 glycoprotein L is nonessential for infectivity but triggers virion endocytosis during entry.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dbcde25aa7a106f9c49a0a9e6c9ff53e"><gtr:id>dbcde25aa7a106f9c49a0a9e6c9ff53e</gtr:id><gtr:otherNames>L?t? C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>pm_13488_28_22205754</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9A149F5E-6F07-4D98-8559-BC29581DA49B</gtr:id><gtr:title>IgG fc receptors provide an alternative infection route for murine gamma-herpesvirus-68.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a3604fe9f45c2b46d2b2aa6c961e27cc"><gtr:id>a3604fe9f45c2b46d2b2aa6c961e27cc</gtr:id><gtr:otherNames>Rosa GT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>128CAB00E3F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DBDC61A9-1CFD-4D83-86B2-DF5B1C1E5CB6</gtr:id><gtr:title>The murine gammaherpesvirus-68 gp150 acts as an immunogenic decoy to limit virion neutralization.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/91f330085c6fe4ace5adc3ac2191d63a"><gtr:id>91f330085c6fe4ace5adc3ac2191d63a</gtr:id><gtr:otherNames>Gillet L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>F12F411F45C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EF68D03A-1D13-49F3-8342-4AFBD81A3A3B</gtr:id><gtr:title>The Murid Herpesvirus-4 gL regulates an entry-associated conformation change in gH.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/91f330085c6fe4ace5adc3ac2191d63a"><gtr:id>91f330085c6fe4ace5adc3ac2191d63a</gtr:id><gtr:otherNames>Gillet L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>E704F50C782</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C6F41A67-3D6C-4896-8F71-0F9F51D9B46A</gtr:id><gtr:title>The murid herpesvirus-4 gH/gL binds to glycosaminoglycans.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/91f330085c6fe4ace5adc3ac2191d63a"><gtr:id>91f330085c6fe4ace5adc3ac2191d63a</gtr:id><gtr:otherNames>Gillet L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>D86FDC34E0F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>27418F8C-B5BC-4AA1-991C-D20890452E74</gtr:id><gtr:title>A gamma-herpesvirus glycoprotein complex manipulates actin to promote viral spread.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0697c0cd0fc47286f423f42c1dad0197"><gtr:id>0697c0cd0fc47286f423f42c1dad0197</gtr:id><gtr:otherNames>Gill MB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>768AF5E8457</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AB2EDD51-BE84-4856-B2DD-D990A57DB27B</gtr:id><gtr:title>Glycosaminoglycan interactions in murine gammaherpesvirus-68 infection.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/91f330085c6fe4ace5adc3ac2191d63a"><gtr:id>91f330085c6fe4ace5adc3ac2191d63a</gtr:id><gtr:otherNames>Gillet L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>326C4BD06C5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CDE83404-567C-4C68-BABA-02ECFE92EBE4</gtr:id><gtr:title>Antibody evasion by the N terminus of murid herpesvirus-4 glycoprotein B.</gtr:title><gtr:parentPublicationTitle>The EMBO journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/91f330085c6fe4ace5adc3ac2191d63a"><gtr:id>91f330085c6fe4ace5adc3ac2191d63a</gtr:id><gtr:otherNames>Gillet L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0261-4189</gtr:issn><gtr:outcomeId>B95618175A5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E8C7174E-F5EF-4E45-B6D4-3B9FC04F884F</gtr:id><gtr:title>Glycoprotein B switches conformation during murid herpesvirus 4 entry.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/91f330085c6fe4ace5adc3ac2191d63a"><gtr:id>91f330085c6fe4ace5adc3ac2191d63a</gtr:id><gtr:otherNames>Gillet L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>266236D1915</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>05D714E5-9CC3-41C7-AFD7-AB462139B04B</gtr:id><gtr:title>Dendritic cells present lytic antigens and maintain function throughout persistent gamma-herpesvirus infection.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f3f5feb21f7510ed8b7941c4f98ae838"><gtr:id>f3f5feb21f7510ed8b7941c4f98ae838</gtr:id><gtr:otherNames>Kupresanin F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>585d4ea97afa59.92652073</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B8B06067-09EC-44B4-9AAD-57B4B1BB3F97</gtr:id><gtr:title>An essential role for the proximal but not the distal cytoplasmic tail of glycoprotein M in murid herpesvirus 4 infection.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4ae4bda5e05b638f9857b4ea3568e7ae"><gtr:id>4ae4bda5e05b638f9857b4ea3568e7ae</gtr:id><gtr:otherNames>May JS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>9CA77F81DEC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CD8C0A68-9EB6-446A-A7E3-F65E1D613534</gtr:id><gtr:title>Evidence for a multiprotein gamma-2 herpesvirus entry complex.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/91f330085c6fe4ace5adc3ac2191d63a"><gtr:id>91f330085c6fe4ace5adc3ac2191d63a</gtr:id><gtr:otherNames>Gillet L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>B79AA5686D3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>67A53618-7AEC-45C8-867E-5AE55D047BC4</gtr:id><gtr:title>Intercellular gamma-herpesvirus dissemination involves co-ordinated intracellular membrane protein transport.</gtr:title><gtr:parentPublicationTitle>Traffic (Copenhagen, Denmark)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4ae4bda5e05b638f9857b4ea3568e7ae"><gtr:id>4ae4bda5e05b638f9857b4ea3568e7ae</gtr:id><gtr:otherNames>May JS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>1398-9219</gtr:issn><gtr:outcomeId>80E9289F80E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>89E12BA7-C7CE-4E4E-8150-ACF28F91B4D2</gtr:id><gtr:title>Post-exposure vaccination improves gammaherpesvirus neutralization.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/91f330085c6fe4ace5adc3ac2191d63a"><gtr:id>91f330085c6fe4ace5adc3ac2191d63a</gtr:id><gtr:otherNames>Gillet L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>A1A25063E96</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>30F88766-A95F-4CC6-9DAB-04A5D8D5AE4B</gtr:id><gtr:title>A single CD8+ T cell epitope sets the long-term latent load of a murid herpesvirus.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/869f3cc10e58c60a111e7020448c548a"><gtr:id>869f3cc10e58c60a111e7020448c548a</gtr:id><gtr:otherNames>Marques S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>C988E7ECC8E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A3EC919A-37C7-4F24-A10F-1529615DD5E2</gtr:id><gtr:title>Herpesvirus glycoproteins undergo multiple antigenic changes before membrane fusion.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6f2397ac70dc5d137bb44df3c2569de8"><gtr:id>6f2397ac70dc5d137bb44df3c2569de8</gtr:id><gtr:otherNames>Glauser DL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_13488_28_22253913</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>21695492-E21C-4DE7-A5D8-DD9EF0635CEA</gtr:id><gtr:title>CD4+ T cells specific for a model latency-associated antigen fail to control a gammaherpesvirus in vivo.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2a2dbbe69cc9fd409a6a04eaf7bfd66a"><gtr:id>2a2dbbe69cc9fd409a6a04eaf7bfd66a</gtr:id><gtr:otherNames>Smith CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>3091A2B1C6D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1A27C079-FEC4-4F46-AD68-0E4D5D3061AF</gtr:id><gtr:title>Murine gammaherpesvirus-68 glycoprotein B presents a difficult neutralization target to monoclonal antibodies derived from infected mice.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/91f330085c6fe4ace5adc3ac2191d63a"><gtr:id>91f330085c6fe4ace5adc3ac2191d63a</gtr:id><gtr:otherNames>Gillet L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>EC430300340</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>34D11EAE-23E4-4744-82F0-41C134E86346</gtr:id><gtr:title>In vivo importance of heparan sulfate-binding glycoproteins for murid herpesvirus-4 infection.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/91f330085c6fe4ace5adc3ac2191d63a"><gtr:id>91f330085c6fe4ace5adc3ac2191d63a</gtr:id><gtr:otherNames>Gillet L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>A1826150E7C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9D23C301-9128-411D-8CF9-638D6C09C572</gtr:id><gtr:title>Multiple functions for ORF75c in murid herpesvirus-4 infection.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8f25d0b0c3441d39861c4c4befbc085c"><gtr:id>8f25d0b0c3441d39861c4c4befbc085c</gtr:id><gtr:otherNames>Gaspar M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>70EA77C0935</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F522F0DD-7311-4C30-B70D-B8AFA58FBE7E</gtr:id><gtr:title>Glycoprotein L disruption reveals two functional forms of the murine gammaherpesvirus 68 glycoprotein H.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/91f330085c6fe4ace5adc3ac2191d63a"><gtr:id>91f330085c6fe4ace5adc3ac2191d63a</gtr:id><gtr:otherNames>Gillet L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>258FE13DC6E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7ABD54AA-81FF-4C97-B096-DB69A4CB5FF5</gtr:id><gtr:title>Murine gammaherpesvirus-68 glycoprotein H-glycoprotein L complex is a major target for neutralizing monoclonal antibodies.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0697c0cd0fc47286f423f42c1dad0197"><gtr:id>0697c0cd0fc47286f423f42c1dad0197</gtr:id><gtr:otherNames>Gill MB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>BC0317D8709</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8F2B9177-310E-4ED9-9406-F01EAA1B8F44</gtr:id><gtr:title>Myeloid infection links epithelial and B cell tropisms of Murid Herpesvirus-4.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8c05e7f57cadf260a1234bb1642ccda3"><gtr:id>8c05e7f57cadf260a1234bb1642ccda3</gtr:id><gtr:otherNames>Frederico B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>pm_13488_28_23028329</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>556DC663-45E2-4317-B6F2-32A417BB56BA</gtr:id><gtr:title>Virion endocytosis is a major target for murid herpesvirus-4 neutralization.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6f2397ac70dc5d137bb44df3c2569de8"><gtr:id>6f2397ac70dc5d137bb44df3c2569de8</gtr:id><gtr:otherNames>Glauser DL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>pm_13488_28_22377583</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EF4EA81E-D1D5-4E47-8FE8-E0229E2C6230</gtr:id><gtr:title>Murine gammaherpesvirus-68 inhibits antigen presentation by dendritic cells.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2a2dbbe69cc9fd409a6a04eaf7bfd66a"><gtr:id>2a2dbbe69cc9fd409a6a04eaf7bfd66a</gtr:id><gtr:otherNames>Smith CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>DAC330ADC5F</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0400427</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CDB856E6-DF2D-4D96-88BD-1CC96FE277EF</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.2  Factors relating to physical environment</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>